Imugene Limited tapping breast cancer market via oncolytic virus CHECKvacc

Be the First to Comment Read

Imugene Limited tapping breast cancer market via oncolytic virus CHECKvacc

There is a desperate need for novel therapies to improve the clinical outcome of TNBC. Imugene expects CHECKvacc to provide an improved outcome for women diagnosed with TNBC each year. Last year, the City of Hope® dosed the second patient in the Phase I clinical trial of CHECKvacc. Watch this video on Kalkine TV. 

Disclaimer

Speak your Mind

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK